Company profile
PD-Rx Pharmaceuticals, Inc.
OTC: PDRX · Healthcare · Medical - Distribution
#560 of 1,418 Healthcare companies by revenue37th-percentile growth
EA Score
70BFH 79DQ —GM 46SS 65
v0.1 · 45/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$18.3M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$257.5k
Employees
142
as of 2026-08-02
Market cap
$5.7M
as of 2026-08-02
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$18.3M$18.3M2024
Net income-$257.5k-$257.5k2024
Operating income-$477.4k-$477.4k2024
Total assets$12.0M$12.0M2024
Liabilities$1.7M$1.7M2024
Equity$10.2M$10.2M2024
Revenue trend
FY2017 – FY2024 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is PD-Rx Pharmaceuticals, Inc.’s revenue?
PD-Rx Pharmaceuticals, Inc. booked $18.3M in FY2024 revenue, contracting 3.2% year over year — slower than 63% of Healthcare companies we track, at a -1.4% net margin.
Peers · Healthcare
Rennova Health, Inc.——OmniAb, Inc.50DFuse Medical, Inc.——Avicanna Inc.55CTrees Corporation——Marpai, Inc.34DNeighbors
Oklahoma →Key facts
CEORobert D. Holsey
SectorHealthcare
IndustryMedical - Distribution
HeadquartersOklahoma City, OK
ExchangeOTC: PDRX
Employees142
IPO date2000-03-09
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.